Skip to main content
FENC
NASDAQ Life Sciences

Fennec Pharmaceuticals Partners with Tampa General to Study PEDMARK® in Adult Cancer Patients

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$8.2
Mkt Cap
$273.12M
52W Low
$4.68
52W High
$9.92
52W Position info
75% above low
Off High info
17% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

FENC sits 75% above its 52-week low of $4.68.

Summary

Fennec Pharmaceuticals announced a clinical research collaboration with Tampa General Hospital Cancer Institute. The study will evaluate the real-world clinical utility of PEDMARK® (sodium thiosulfate injection) in reducing ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin chemotherapy. This collaboration follows Fennec's recent announcement of positive real-world data for PEDMARK® in adult head and neck cancer patients, indicating a continued focus on expanding the evidence base and market for their key product. While PEDMARK® is currently approved for pediatric patients and recommended for AYA patients, this collaboration aims to generate further real-world evidence for its use in a broader adult population. This can support wider adoption, inform future clinical research, and potentially lead to label expansion or updated treatment guidelines, strengthening the long-term commercial prospects of PEDMARK®. Traders will monitor the progress and results of this study, as positive outcomes could further solidify PEDMARK®'s position in the market and expand its addressable patient population.

At the time of this announcement, FENC was trading at $8.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $273.1M. The 52-week trading range was $4.68 to $9.92. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

FENC - Latest Insights

FENC
Nov 12, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $10.90
Real-time Price: $13.41 info
Change: +$2.51 (+23%) info
Market Cap: $474.854M info
FENC
Nov 12, 2026, 6:06 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $10.64
Real-time Price: $13.41 info
Change: +$2.77 (+26%) info
Market Cap: $474.854M info
FENC
Sep 17, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.78
Real-time Price: $13.41 info
Change: +$2.63 (+24%) info
Market Cap: $474.854M info
FENC
Sep 17, 2026, 7:30 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $10.55
Real-time Price: $13.41 info
Change: +$2.86 (+27%) info
Market Cap: $474.854M info
FENC
Aug 13, 2026, 4:03 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $12.06
Real-time Price: $13.41 info
Change: +$1.35 (+11%) info
Market Cap: $474.854M info